UNSPSC 51313114: Chlorcyclizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NPB7A7874U, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-methyl-, monohydrochloride but more generally known as chlorcyclizine hydrochloride, which bears US NIH Compound Identifier 2710. European Medicines Agency schedules Chlorcyclizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01212MIG.

UNSPSC 51313114 Chlorcyclizine hydrochloride is a Commodity code that nominally describes a specific antihistamine compound, but the recent state and local procurement activity recorded under this code does not align with that pharmaceutical specification. The single identified opportunity, Seminole County, Florida's IFB 60459723LAS, solicits naloxone and drug deactivation systems — emergency overdose-reversal medication and harm-reduction equipment — which fall outside the chlorcyclizine hydrochloride scope. This mismatch suggests either a tagging error in the source database or that the code is not actively used for relevant state and local purchasing. No other recent opportunities appear under this Commodity code.

The Seminole County solicitation, posted June 30, 2026, with a response deadline of July 26, 2023, requests 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The IFB requires vendors to submit bids electronically, include all shipping and delivery costs in proposals, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify employment eligibility verification and federal environmental regulations. The contract term spans two years with an optional one-year renewal and includes a three-month probationary period allowing termination at will. Potential FEMA funding adds compliance obligations. Given the single unrelated opportunity and the clear divergence between the code's pharmaceutical name and actual procurement activity, this code shows little actionable signal for business development in state and local naloxone or harm-reduction equipment supply.